TICKERNERD
Menu
TLSITLSIHealthcare · Medical Devices

TLSI Stock Forecast: TriSalus Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$4.13
−2.82% on the day

The 5 Wall Street analysts covering TriSalus Life Sciences, Inc. hold a median 12-month price target of $11 — +166.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$261.7M
Ticker Nerd rank
32 / 100
Median analyst target
$11
Analysts covering
5
Revenue$11.4M+1.7% y/y
Operating income−$9.8M
Net income−$9.2M
Free cash flow−$10.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
−12.7%
YTD
−40.8%
1Y
−14.8%
From 52W high
−44.9%
From 52W low
+63.9%
$2.52
$7.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TriSalus Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
65
Size
65
Volatility
50
Revisions
47
Momentum
45
Quality
43
Growth
39
Value
36
Issuance
14

Accruals (65): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TLSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26TLSIHigh $14Median $11Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $7Median $11High $14

The green dot is the last close — the median target sits +166.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2026HC Wainwright & Co.MaintainsBuy$11 → $12
9 Sept 2026HC Wainwright & Co.InitiatesBuy$11
9 Sept 2026HC Wainwright & Co.InitiatesBuy—
13 May 2026Lake StreetMaintainsBuy—
13 May 2026Lake StreetMaintainsBuy$10 → $8.00
9 Mar 2026Canaccord GenuityMaintainsBuy—
6 Mar 2026Canaccord GenuityMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
28 Mar 2025Canaccord GenuityMaintainsBuy—
13 Feb 2025Lake StreetInitiatesBuy—
24 Jan 2025Roth MKMReiteratesBuy—
17 Dec 2024Cantor FitzgeraldInitiatesOverweight—
15 Nov 2024Canaccord GenuityMaintainsBuy—
11 Nov 2024Roth MKMInitiatesBuy—
25 Oct 2024Northland Capital MarketsInitiatesOutperform—
16 Sept 2024OppenheimerInitiatesOutperform—
27 June 2024Canaccord GenuityMaintainsBuy—
30 May 2024Canaccord GenuityInitiatesBuy—
10 May 2024JonesTradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TLSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TLSI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, TriSalus Life Sciences, Inc. returned −14.8% against +16.2% for the S&P 500, dividends included.

TLSI vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Jan 26Apr 26Jul 26Oct 26TLSIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TLSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

TriSalus Life Sciences, Inc. (TLSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
5.8×

Cheaper than 22% of US stocks

Price / book
39.7×

Cheaper than 3% of US stocks

EV / EBITDA
−8.4×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
1.7%

Higher than 31% of US stocks

Earnings growth (YoY)
1.7%

Higher than 38% of US stocks

Gross margin
86.8%

Higher than 95% of US stocks

Operating margin
−86.0%

Higher than 14% of US stocks

Net margin
−62.6%

Higher than 9% of US stocks

Returns & dividend
Return on equity
205.8%

Higher than 98% of US stocks

Return on assets
−36.8%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TriSalus Life Sciences, Inc. (TLSI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TriSalus Life Sciences, Inc. has a market value of $261.7M and an enterprise value of $251.1M.

  • Revenue in the twelve months to 30 June 2026: $45.1M. The latest quarter grew 1.7% year on year.

  • Net income over the same four quarters: −$28.2M, a −62.6% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.30.

  • Free cash flow in the twelve months to 30 June 2026: −$23.3M.

  • Shares outstanding: 61.5M.

  • Trailing P/E: 0.1×; forward P/E: −17.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • TriSalus Life Sciences, Inc. employs 102 people — $442K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

TLSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TLSITriSalus Life Sciences, Inc.$261.7M
32
TMCITreace Medical Concepts, Inc.$246.9M
53
LABStandard BioTools, Inc.$261.5M
26
QSIQuantum-Si, Inc.$262.9M
36
ELMDElectromed, Inc.$231.9M
92
INFUInfuSystem Holdings, Inc.$267.1M
100
MOBIMobia Medical, Inc.$283.2M
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TriSalus Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TLSI news & analysis

TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support

Benzinga · 23 Sept 2026positive

The U.S. Food and Drug Administration granted 510(k) clearance for TriSalus Life Sciences' (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio. This regulatory milestone comes as the company's stock tests key support.

Why it matters — A TLSI watcher would care because FDA clearance for a new product in the PEDD portfolio expands the company's commercial pipeline at a time when its stock is testing a key support level.

TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday

Benzinga · 23 Sept 2026negative

U.S. stocks were lower, with the Nasdaq Composite falling over 100 points on Wednesday, while TriSalus Life Sciences was among the big stocks moving higher. The item is a brief market-movers note listing the gainers for the session.

Why it matters — A TLSI watcher would note that the company's shares gained ground on a day when the broader market, including the Nasdaq, declined.

TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization

Business Wire · 22 Sept 2026positive

TriSalus Life Sciences announced it received U.S. FDA 510(k) clearance for TriNav® Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio for liver embolization. The clearance expands the company's PEDD product lineup.

Why it matters — FDA clearance of a new product in its core PEDD portfolio could broaden TriSalus's commercial offerings for liver embolization procedures.

TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference

Business Wire · 31 Aug 2026neutral

TriSalus Life Sciences, Inc. announced it will participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference. The company's participation in the event was announced via a Business Wire release from Westminster, Colorado.

Why it matters — TLSI watchers may gain insight from the company's presentation and investor engagement at a major industry investment conference.

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

MarketBeat · 18 Aug 2026neutral

TriSalus Life Sciences presented at Canaccord Genuity's Global Growth Conference, outlining its commercial expansion, product pipeline, and clinical-evidence strategy. Management emphasized the company's pressure-enabled delivery technology for solid-tumor treatments.

Why it matters — TLSI watchers would value insight into the company's commercial strategy, pipeline progress, and the clinical evidence behind its pressure-enabled delivery technology for solid tumors.

FAQ

Frequently asked questions about TLSI stock

What is the TLSI stock price forecast for 2026-2027?

The 5 Wall Street analysts covering TriSalus Life Sciences, Inc. have a median 12-month price target of $11, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLSI stock a buy right now?

Of the 5 analysts covering TriSalus Life Sciences, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TriSalus Life Sciences, Inc. 32 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLSI?

As at 8 Oct 2026, TriSalus Life Sciences, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (65 of 100).

Will TLSI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +166.3% from the last close, and Ticker Nerd's factor model ranks TriSalus Life Sciences, Inc. 32 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLSI stock forecast for 2030?

No analyst covering TriSalus Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.

How has TLSI stock performed over the past year?

TriSalus Life Sciences, Inc. returned -14.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TriSalus Life Sciences, Inc. do?

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers.

What is the latest news on TLSI?

The most recent item we track (Benzinga, 23 Sept 2026): "TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support". The U.S. Food and Drug Administration granted 510(k) clearance for TriSalus Life Sciences' (NASDAQ:TLSI) TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery (PEDD) portfolio. This regulatory milestone comes as the company's stock tests key support.

Company

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers. Its current product portfolio centers on Pressure-Enabled Drug Delivery (PEDD) platforms, including the TriNav infusion system for hepatic arterial procedures and the Pancreatic Retrograde Venous Infusion device. TriSalus also advances nelitolimod, an investigational immunotherapeutic designed to work alongside standard treatments in solid tumors. The company’s products and clinical programs are aimed at improving how therapies reach tumor sites, particularly where conventional delivery faces anatomical and physiological barriers. TriSalus Life Sciences, Inc. serves the interventional oncology and medical device markets, combining device-based delivery with oncology therapeutics to support physicians treating liver cancer, liver metastases, and pancreatic tumors.

CEO Ms. Mary T. Szela B.S.N., M.B.A. · 102 employees · United States · https://trisaluslifesci.com